Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1356225 in Healthy Men
NCT04065295Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1356225 in obesity and Overweight (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of subjects with drug-related adverse events up to 30 days. Started Sep 2019; status: completed.
02
Drugs
BI 1356225
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04065295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065295.